This article is more than 2 year old.

Gilead's antiviral remdesivir gets US FDA nod for emergency use in COVID treatment

Gilead's antiviral remdesivir gets US FDA nod for emergency use in COVID treatment
Drug firm Gilead has said that  the US Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for its investigational antiviral remdesivir to treat COVID-19.
This will facilitate broader use of remdesivir to treat hospitalized patients with severe COVID-19 disease, enabling access to remdesivir at additional
hospitals across the country., the company said.
However, the  authorization is temporary and Gilead will still have to go through the usual process of new drug application submission, review and approval process of the US FDA. It still remains an investigational drug and has not been approved by the regulator, Gilead said.
The currently limited available supply of remdesivir will be allocated to "appropriate patients in urgent need of treatment,", the company said.
The US government will coordinate the donation and distribution of remdesivir to hospitals in cities most heavily impacted by COVID-19. Hospitals with intensive care units and other hospitals that the government deems most in need will receive priority in the distribution of remdesivir, the company said.
The optimal duration of treatment is still being studied in ongoing clinical trials. Under the EUA, both 5-day and 10-day treatment durations are suggested, based on the severity of disease.  The EUA allows for the distribution and emergency use of remdesivir only for the treatment of
COVID-19.
next story

Market Movers

Currency

CompanyPriceChng%Chng